Education
About Us
Working with TipRanks
Follow Us
BB Biotech (0JYO) (CH:BION)
:BION
Total Valuation
BB Biotech has a market cap or net worth of CHF1.49B. The enterprise value is -CHF351.26M.
Market CapCHF1.49B
Enterprise Value-CHF351.26M
Share Statistics
BB Biotech has 55,400,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding55,400,000
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
BB Biotech’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee―
Profits Per Employee―
Employee Count―
Asset Turnover-0.08
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of BB Biotech is -11.34. BB Biotech’s PEG ratio is 0.27.
PE Ratio-11.34
PS Ratio―
PB Ratio1.01
Price to Fair Value1.01
Price to FCF10.73
Price to Operating Cash Flow10.73
PEG Ratio0.27
Income Statement
In the last 12 months, BB Biotech had revenue of -199.57M and earned -206.61M in profits. Earnings per share was -3.77.
Revenue-199.57M
Gross Profit-199.57M
Operating Income-29.93M
Pretax Income-206.53M
Net Income-206.61M
EBITDA-201.26M
Earnings Per Share (EPS)-3.77
Cash Flow
In the last 12 months, operating cash flow was 97.09M and capital expenditures 0.00, giving a free cash flow of 146.18M billion.
Operating Cash Flow97.09M
Free Cash Flow146.18M
Free Cash Flow per Share2.64
Dividends & Yields
BB Biotech pays an annual dividend of CHF1.799, resulting in a dividend yield of 6.79%
Dividend Per ShareCHF1.799
Dividend Yield6.79%
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.02
52-Week Price Change-27.60%
50-Day Moving Average32.27
200-Day Moving Average35.19
Relative Strength Index (RSI)36.71
Average Volume (3m)124.09K
Important Dates
BB Biotech upcoming earnings date is Apr 25, 2025, TBA Not Confirmed.
Last Earnings DateJan 24, 2025
Next Earnings DateApr 25, 2025
Ex-Dividend DateMar 21, 2025
Financial Position
BB Biotech as a current ratio of 158.32, with Debt / Equity ratio of 0.00%
Current Ratio158.32
Quick Ratio158.32
Debt to Market Cap0.00
Net Debt to EBITDA―
Interest Coverage Ratio-5.16
Taxes
In the past 12 months, BB Biotech has paid 79.00K in taxes.
Income Tax79.00K
Effective Tax Rate>-0.01
Enterprise Valuation
BB Biotech EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
BB Biotech has CHF2.25M in cash and marketable securities with CHF344.70M in debt, giving a net cash position of -CHF2.25M billion.
Cash & Marketable SecuritiesCHF2.25M
Total DebtCHF344.70M
Net Cash-CHF2.25M
Net Cash Per Share-CHF0.04
Tangible Book Value Per ShareCHF42.39
Margins
Gross margin is 160.80%, with operating margin of 15.00%, and net profit margin of 103.53%.
Gross Margin160.80%
Operating Margin15.00%
Pretax Margin103.49%
Net Profit Margin103.53%
EBITDA Margin100.85%
EBIT Margin100.58%
Analyst Forecast
The average price target for BB Biotech is CHF66.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetCHF66.00
Price Target Upside131.99% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast―